Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
N. Engl. J. Med 2021 Aug 12;385(7)595-608, RJ Landovitz, D Donnell, ME Clement, B Hanscom, L Cottle, L Coelho, R Cabello, S Chariyalertsak, EF Dunne, I Frank, JA Gallardo-Cartagena, AH Gaur, P Gonzales, HV Tran, JC Hinojosa, EG Kallas, CF Kelley, MH Losso, JV Madruga, K Middelkoop, N Phanuphak, B Santos, O Sued, J Valencia Huamaní, ET Overton, S Swaminathan, C Del Rio, RM Gulick, P Richardson, P Sullivan, E Piwowar-Manning, M Marzinke, C Hendrix, M Li, Z Wang, J Marrazzo, E Daar, A Asmelash, TT Brown, P Anderson, SH Eshleman, M Bryan, C Blanchette, J Lucas, C Psaros, S Safren, J Sugarman, H Scott, JJ Eron, SD Fields, ND Sista, K Gomez-Feliciano, A Jennings, RM Kofron, TH Holtz, K Shin, JF Rooney, KY Smith, W Spreen, D Margolis, A Rinehart, A Adeyeye, MS Cohen, M McCauley, B GrinsztejnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.